3D-Conformal Radiation vs Helical Tomotherapy in Prostate Cancer
Prostate Cancer
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring prostate, IMRT, tomotherapy, radiation, cancer
Eligibility Criteria
Inclusion Criteria: A pathologic diagnosis of adenocarcinoma of the prostate Age greater than 18 years ECOG performance status of 2 or less. Presence of any of the following high risk features: Clinical stage cT3-4 or Gleason score 8-10 or Pre-treatment PSA > 20ng/ml or Clinical N1/N2 or pathologic N1/N2 Exclusion Criteria: Patients with contraindication to radical radiation therapy including inflammatory bowel disease Prior or active malignancy except non-melanoma skin carcinoma within 5 years of the diagnosis of prostate cancer Prior pelvic radiotherapy for other malignancies Prior cytotoxic chemotherapy Prior orchiectomy, radical prostatectomy, cryotherapy or thermal ablation therapy for prostate cancer
Sites / Locations
- The Ottawa Hospital Regional Cancer Centre
Arms of the Study
Arm 1
Arm 2
Other
Experimental
Arm A: 3D-Conformal Radiation
Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy
Intervention: Standard radiation treatment for high risk prostate cancer. Once daily Monday to Friday for 8 weeks. 3DCRT 7800 cGY/39 Fractions/ STD Technique* Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23 Boost 6 F 3DCRT to Prostate 3,200 cGy/16
Intervention: Helical Tomotherapy Intensity Modulated Radiotherapy (IMRT) once daily Monday to Friday for 8 weeks. IMRT using Helical Tomotherapy* 7800 cGY/39 Fractions Boost IMRT to Prostate 3,200 cGy/16